Cancers, Vol. 9, Pages 117: Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

We present FLAVINO data arguing for further development of cilengitide plus cetuximab in treatment of a subgroup of HNSCC potentially identified by the FLAVINO assay using a set of biomarkers for response evaluation.

Source: Cancers - September 5, 2017 Category: Cancer & Oncology Authors: Susan Cedra Susanne Wiegand Marlen Kolb Andreas Dietz Gunnar Wichmann Tags: Article Source Type: research